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Macrophages were distributed throughout the tumour,
but were increased around areas of necrosis and
around blood vessels. No relationship between
tumour cell proliferation and necrosis was detected.
Conclusions: Tumour cell proliferation is concentrated
around blood vessels in glioblastomas. Blood vessel
proliferation, but not tumour cell proliferation, is related
to areas of necrosis and the presence of macrophages
in glioblastomas. Targeting of blood vessel proliferation
and macrophages within glioblastoma may present a
therapeutic strategy for treatment of these devastating
tumours.
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Loss of chromosome 10, retinoblastoma and
deleted-in-colon-carcinoma (DCC) proteins in
glioblastomas
Introduction: Glioblastomas have a median survival of
9–12 months. However, some patients die within a few
weeks of diagnosis and others may survive for 2 years
or more. To try to predict survival more accurately, we
have evaluated a number of morphological, immuno-
histochemical and molecular markers in a retrospective
series of glioblastomas. Material and methods: Parafﬁn
sections from 107 consecutive glioblastomas diagnosed
between 1993 and 1997 were included in the study.
All cases were reviewed and the presence of calciﬁca-
tion or oligodendroglioma-like areas noted. Sections
were immunostained with commercial antibodies to
retinoblastoma and DCC proteins and subjected to
in situ hybridization with probes to chromosomes 12
and 10. Results: Loss of retinoblastoma and DCC protein
expression was seen in 20% and 71% of glioblastomas
respectively. Loss of retinoblastoma protein expression
correlated with poor outcome (P=0.045). 64% of glio-
blastomas showed loss of chromosome 10 but this
did not have a signiﬁcant association with survival.
The ﬁve tumours with oligodendroglioma-like areas
had a median survival of 70 weeks, compared with
27 weeks for those without (P=0.014). Conclusion: In
this study, age, loss of retinoblastoma protein and
a lack of oligodendroglioma-like areas were predictors
of signiﬁcantly shorter survival in glioblastomas.
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The role of the cysteine proteinase cathepsin S
in astrocytoma invasion
Introduction: Local tumour invasion gives rise to recur-
rence after surgical resection, leading to the poor
prognosis associated with malignant astrocytomas.
Extracellular proteolytic enzymes including cysteine
proteinases have been implicated in facilitating
tumour cell invasion. The current study was designed
to characterize the expression of the cysteine proteinase,
cathepsin S and investigate its potential role in the
invasive process. Materials and methods: Expression of
cathepsin S was investigated in astrocytoma biopsies by
immunohistochemistry and in astrocytoma cultures by
immunocytochemistry and the reverse transcription
polymerase chain reaction. Cathepsin S activity assays
were also performed on in vitro and in vivo samples.
An in vitro Matrigel invasion assay was used to
evaluate the effect of selective cathepsin S inactivation,
by the inhibitor LHVS, on glioblastoma cell invasion.
Results: Cathepsin S immunostaining was restricted
to tumour cells in vivo. Cathepsin S transcript, protein
and activity were observed within astrocytoma cells
in vitro. Extracellular cathepsin S activity was about
ﬁve-fold higher in cultures from grade IV tumours
than in lower grades. Inhibition of cathepsin S with
0.01 mM LHVS signiﬁcantly inhibited in vitro invasion
of the glioblastoma cell line U251 mg by 50%
(P<0.0001). Conclusions: It has been demonstrated
for the ﬁrst time that cathepsin S is expressed and
secreted by astrocytoma cells and plays a role in
astrocytoma invasion, and is therefore a potential
therapeutic target.
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The expression of the EGF receptor family and
their ligands in human medulloblastomas
Introduction: Little is known about the molecular
processes behind the development of medulloblastomas.
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